Study of Δ8-Tetrahydrocannabivarin in Healthy Participants
Author Information
Author(s): Sempio Cristina, Campos-Palomino Jorge, Klawitter Jelena, Peters Erica N., MacNair Laura, Haghdoost Mehdi, Bonn-Miller Marcel O., Harrison Amy, Babalonis Shanna, Christians Uwe, Klawitter Jost
Primary Institution: University of Colorado, Anschutz Medical Campus
Hypothesis
What are the pharmacokinetics of Δ8-tetrahydrocannabivarin (THCV) and its metabolites in healthy participants after oral administration?
Conclusion
The study found that Δ8-THCV and its main metabolites are dose-linear in pharmacokinetics after oral administration.
Supporting Evidence
- Δ8-THCV was found to be safe and well tolerated in participants.
- The main metabolite detected was Δ8-THCV-COOH.
- Plasma concentrations of Δ8-THCV-COOH were significantly higher than Δ8-THCV.
- Time to maximum concentration (tmax) ranged from 3.8 to 5.0 hours for Δ8-THCV.
- AUClast showed dose linearity for Δ8-THCV and its metabolites.
- Δ9-THCV and Δ9-THCV-COOH were detected in plasma despite being absent in the formulation.
- Further studies are needed to understand the conversion mechanism to Δ9-THCV.
- The study provides foundational data for future research on Δ8-THCV's therapeutic potential.
Takeaway
This study looked at how a cannabis compound called Δ8-THCV behaves in the body after people take it. It found that the amount in the blood increases with higher doses.
Methodology
Participants received different doses of Δ8-THCV in a placebo-controlled trial, and blood samples were taken to analyze the pharmacokinetics.
Limitations
The short plasma collection time limited the ability to calculate certain pharmacokinetic parameters.
Participant Demographics
Healthy participants aged 18-55 were included in the study.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website